multiple sclerosis | pharmaphorum

Friday 20 March 2026

multiple sclerosis

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

News

MSD and Mayo Clinic at screen

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

News

Roche hq

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

A pregnant woman with her hands forming a heart shape over her bump, wearing a beige sweater

NICE recommends wider use of MS drug natalizumab via NHS

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

News

No Christmas present for Sanofi, as FDA turns down MS drug

No Christmas present for Sanofi, as FDA turns down MS drug

FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.

News

Sanofi gets double blow for MS drug tolebrutinib

Sanofi gets double blow for MS drug tolebrutinib

Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.